Introduction
============

Myocardial infarction (MI), a common presentation for ischemic heart disease/coronary artery disease, is a major contributor to mortality rates worldwide ([@b1-etm-0-0-7320]). The major trigger of MI is generally owing to thrombus formation in a coronary artery. Accordingly, the current treatments mainly include medical therapy (e.g. anticoagulant medications, antiplatelets) and elective catheterization. However, some disadvantages can not be ignored, such as high risk of bleeding in medical therapy and high cost of treatment in elective catheterization ([@b2-etm-0-0-7320]). In order to effectively prevent and treat MI, seeking the exact pathogenesis of MI at various aspects is necessary. Currently research directions mainly include improvement of coronary blood flow, inhibition of apoptosis, reduction of oxygen consumption, and revascularization procedures ([@b3-etm-0-0-7320]). However, few studies have been conducted in the pathogenesis of MI at the non-coding RNA (ncRNA) level.

ncRNAs, RNA molecules, are not translated into proteins, which mainly include ribosomal RNAs (rRNAs), transfer RNAs (tRNAs), short non-coding RNAs such as microRNAs (miRNAs) and the long non-coding RNAs (lncRNAs). lncRNAs are a set of RNAs longer than 200 nucleotides, and participate in many fundamental biological processes mainly including genomic imprinting and chromatin modification ([@b4-etm-0-0-7320]). Although the effects of lncRNAs on various cancers ([@b5-etm-0-0-7320]) and neuronal diseases ([@b6-etm-0-0-7320],[@b7-etm-0-0-7320]) have been widely investigated, the study number of lncRNA function in cardiovascular diseases is very limited. Currently, some transcripts have been investigated for their potential role as biomarkers of cardiovascular diseases. The mitochondrial lncRNA LIPCAR, as a novel biomarker, can predict future death in heart failure patients ([@b8-etm-0-0-7320]). lncRNA CoroMarker is a diagnostic biomarker for coronary artery disease ([@b9-etm-0-0-7320]). In addition, lncRNA MIAT might regulate MI via functioning as a competing endogenous RNA for various targets ([@b10-etm-0-0-7320],[@b11-etm-0-0-7320]).

miRNAs are short non-coding RNAs (approximately 20 nucleotides) and negatively regulate target genes. Different from lncRNAs, miRNAs have been largely investigated in the context of MI ([@b12-etm-0-0-7320]). The relationship between miRNAs and lncRNAs has been extensively demonstrated, among which lncRNAs can indirectly compete with mRNAs through binding to miRNAs ([@b13-etm-0-0-7320],[@b14-etm-0-0-7320]). For instance, lncRNA CHRF could regulate cardiac hypertrophy by targeting miR-489 ([@b15-etm-0-0-7320]). Recognizing lncRNA competitively regulated subpathway can reveal the pathogenesis of disease and the molecular mechanism of lncRNAs in the disease context. However, the relevant regulated mechanism of lncRNAs in MI remains unclear. Subpathway-LNCE, as a novel method, can effectively integrate lncRNA-mRNA expression profile and identify lncRNA competitively regulated subpathway ([@b16-etm-0-0-7320]). Moreover, subpathway-LNCE method is more accurate, advanced and its calculation results are more relevant to disease. Accordingly, we used the subpathway-LNCE method to investigate pathogenesis of MI at genetic level.

Materials and methods
=====================

### Recruitment and pretreatment of gene expression data

Gene expression profiles with accession number (GSE34198) for MI were recruited from the Gene Expression Omnibus (GEO) (<http://www.ncbi.nlm.nih.gov/geo/>) database. GEO is a public functional genomics data repository that freely distributes high throughput gene expression profiles and other functional genomics data sets. GSE34198 consists of 48 healthy controls and 49 patients with MI, and is deposited on GPL6102 data platform.

For purpose of controlling the quality of GSE34198, GSE34198 was pretreated as follows: Background correction was performed by Robust Multi-array Average (RMA) algorithm ([@b17-etm-0-0-7320]), the normalization was evaluated by quantiles algorithm ([@b18-etm-0-0-7320]), perfect match and mismatch was revised by Micro Array Suite (MAS) algorithm ([@b19-etm-0-0-7320]), and all expression values were summarized by medianpolish method ([@b17-etm-0-0-7320]). After removing invalid or duplicated probes, we converted them into gene symbols by the annotate package ([@b20-etm-0-0-7320]). Thus, 19,027 genes were obtained in the pretreated GSE34198 of MI for further application.

### Constructing the candidate lncRNA-mRNA interactions

As far as we known, small non-coding RNAs target Base version 2.0 (starBase v2.0, <http://starbase.sysu.edu.cn/>) has been used to identify the RNA-RNA and protein-RNA interaction networks. Hence, miRNA-lncRNA interactions and miRNA-mRNA interactions were collected using StarBase v2.0. The miRNA-mRNA interactions were acquired based on miRecords ([@b21-etm-0-0-7320]), mir2Disease ([@b22-etm-0-0-7320]), mirTarBase ([@b23-etm-0-0-7320]) and TarBase ([@b24-etm-0-0-7320]). Then candidate lncRNA-mRNA competitively regulated relationships were constructed using their shared miRNAs between miRNA-mRNA and miRNA-lncRNA interactions. To ensure the data reliability, we used two criteria to identify the candidate competing miRNA of each lncRNA as follows: i) hypergeometric test of shared miRNAs under a threshold of P=0.05 and ii) Jaccard Coefficient of shared miRNAs rank at top 20%.

To make the candidate lncRNA-mRNA interactions involved in MI, all the genes in GSE34198 were mapped on them and the intersections were selected for further analysis.

### Obtaining the lncRNA and mRNA co-expression relationship pairs

To screen the candidate lncRNA-mRNA interactions, we evaluated co-expression for any pair of relations in the candidate lncRNA-mRNA network using Pearson\'s correlation coefficient. Subsequently, the significance of Pearson\'s correlation coefficient was evaluated by Fisher\'s Z-transform, which converts the values into the normally distributed variable Z. Then the Z-transform test utilizes the one-to-one mapping of the standard normal curve to the P-value of a one tailed test. When the calculation value exceeded a significant positive threshold (P\<0.05), the lncRNA-mRNA co-expression relationship pairs (LncGenePairs) were retained.

### Reconstructing condition-specific lncRNA competitively regulated signal pathways

We used Fisher\'s test to identify the gene enrichment pathways in the mRNA-gene expression profiles, and the pathways were obtained from KEGG database. The gene enrichment pathways were collected when the P-value of gene enrichment pathway was no longer than 0.01, and considered as the candidate difference pathways. We put lncRNAs in the LncGenePairs into the candidate difference pathway graphs as nodes, then we acquired condition-specific lncRNA regulated signal pathways (csLncRPs). The lncRNA nodes were considered as signature nodes.

### Located subpathways within pathways according to signature nodes

Signature nodes represent information on the competing regulation and genes of interest, which can help to efficiently locate subpathways through further considering their topologies within pathways. Moreover, distances are usually similar between certain nodes in a subpathway. We utilized 'lenient distance' similarity of signature nodes to locate subpathways competing for regulation by lncRNAs. We computed the shortest path between any two signature nodes as follows: If the molecule number between two signature nodes was less than n, they were combined into a single node. Finally, the node number in the molecule sets within pathway was longer than s, and defined as subpathway regions. The n parameter conducts the intensity of regulated signals, and the s parameter regulates the size of candidate subpathways. Thus, n=1 and s=8 were used as default parameters.

### Statistical significance of candidate subpathways

Wallenius approximation methods were applied to evaluate the statistical significance of each subpathway. The needed values were shown as follows: i) the number of interesting mRNAs (x) submitted for analysis; ii) background mRNAs (n) number; iii) the number of background mRNAs (m1) annotated to each subpathway; iv) the number of interesting mRNAs (m2) annotated to each subpathway and v) the weight of each subpathway (w), which indicated the intensity of competitively regulated lncRNAs involved in this subpathway. The formula of the subpathway weight is as follows:
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According to the formula above, P~G~ represents the number of mRNAs in the subpathways. G~L~ represents the number of mRNAs competing regulation by lncRNAs in this subpathway. Moreover, β is the control parameter (β =1). The Wallenius approximation methods were carried out by R package BiasedUrn ([@b25-etm-0-0-7320]).

### Identifying hub lncRNAs

According to the values of the subpathways, the subpathways competing for regulation by lncRNAs were obtained and constructed, that is, lncRNA-mRNA networks were constructed. Then, we collected the hub lncRNAs when the lncRNA degree was longer than the average lncRNA degree in the lncRNA-mRNA networks.

Results
=======

### Identifying the relationship between lncRNAs and mRNAs for MI

In this study, 19,027 genes were selected from GSE34198 of MI after standard corrections and normalizations. To understand the relationship between lncRNA and mRNA, we extracted lncRNA-mRNA interactions by their shared miRNAs based on mRNA-miRNA interactions and lncRNA-miRNA interactions. All genes in GSE34198 were mapped on these lncRNA-mRNA interactions and the intersections were selected. We then collected these intersections which satisfied P\<0.05. The results revealed that 7,693 lncRNA-mRNA interactions were obtained, which included 835 lncRNAs and 1,749 mRNAs. Next, 1,681 mRNAs and 112 lncRNAs were indentified for MI after taking intersections with 19,027 genes in gene expression data. Subsequently, Pearson\'s correlation coefficient was performed to evaluate co-expression for any pair of relations in the intersections. We obtained 300 lncRNA-mRNA co-expression relationship pairs (LncGenePairs), among which include 58 lncRNAs, and 243 mRNAs. The top 6 LncGenePairs are illustrated in [Table I](#tI-etm-0-0-7320){ref-type="table"}.

### Reconstruction of condition-specific lncRNA competitively regulated signal pathways

In order to obtain the lncRNA competitively regulated signal pathways (csLncRPs), we firstly annotated the mRNAs in the mRNAs-gene expression profiles into KEGG pathways. A total of 62 candidate difference pathways were obtained, among which the top 6 pathways were selected as shown in [Table II](#tII-etm-0-0-7320){ref-type="table"}. We then put lncRNAs based on the LncGenePairs in the candidate difference pathways as nodes through linking to their regulated mRNAs. Hence, a total of 1,241 csLncRPs were acquired, among which the top 14 pathways were selected as shown in [Table III](#tIII-etm-0-0-7320){ref-type="table"}.

### Identifying the signal subpathways competitively regulated by lncRNA for MI

The csLncRPs were calculated using lenient distance similarity to obtain the lncRNA competitively regulated subpathways. Then the Wallenius approximation methods were performed to evaluate the significance of signal subpathways. A total of 65 lncRNA competitively regulated subpathways were obtained, among which the top rank 6 subpathways are listed in [Table IV](#tIV-etm-0-0-7320){ref-type="table"}. We illustrated the schematic diagram of top rank 3 lncRNA competitively regulated subpathways, that is Ribosome, RNA transport and mitogen activated protein kinase (MAPK) subpathways ([Fig. 1](#f1-etm-0-0-7320){ref-type="fig"}). According to the value, the signal subpathways were constructed into lncRNA-mRNA networks. Then 13 hub lncRNAs were collected from the lncRNA-mRNA networks ([Fig. 2](#f2-etm-0-0-7320){ref-type="fig"}).

Discussion
==========

In our study, the subpathway-LNCE method was first used to identify the lncRNAs competitively regulated subpathways for MI. Then the lncRNA-mRNA network was constructed according to these signal subpathways, in which the hub lncRNAs were detected.

Plenty of literature has reported that lncRNAs regulate many fundamental biological processes and play a key role in various diseases ([@b4-etm-0-0-7320],[@b5-etm-0-0-7320]). Besides, lncRNAs competitively regulate mRNA expression levels through binding to miRNAs, so that lncRNAs can maintain normal biological functions ([@b13-etm-0-0-7320],[@b14-etm-0-0-7320]). Hence, identifying the functional relationships between lncRNA and disease relevant subpathways may help understand the pathogenesis of diseases. However, the relevant regulated mechanism of lncRNAs in MI remains unclear. Thus, it is very important to search for a suitable method to examine the functions of lncRNAs in MI.

Therefore, we applied subpathway-LINCE with GEO data set of MI and identified a total of 65 lncRNA competitively regulated subpathways under the condition of P\<0.01. Of which, P-values of 36 subpathways were nearly zero, which showed the significant difference between MI group and control group, such as Ribosome, RNA transport and MAPK subpathways. Ribosome subpathways are critical to ribosome assembly and protein synthesis. When using some methods to regulate the ribosome biogenesis, the cell growth will be extensively affected. For example, mTOR signaling can regulate multiple steps in ribosome biogenesis, thus influencing the cell proliferation and survival ([@b26-etm-0-0-7320],[@b27-etm-0-0-7320]). Moreover, mTOR is activated in MI and mTOR inhibition could reduce cardiac dilation and infract size and improve cardiac function ([@b28-etm-0-0-7320]). Hence, clarifying the effect of ribosome subpathways on MI may offer opportunities for new therapies. RNA transport is the process where specific RNA molecules are transported from one cellular region to another via different sorting and transport mechanisms ([@b29-etm-0-0-7320]). In the present study, RNA transport subpathway in MI was associated with lncRNAs, which might assist in better understanding of the pathogenesis of MI. In particular, MAPK influences mitochondria mediated cell functions, mainly including proliferation, apoptosis and gene expression, because mitochondria are great power providers and gate-keepers of cell life and death. Moreover, MAPK can significantly affect cellular signaling underlying cardiac compensation and decompensation via interacting with the mitochondria ([@b30-etm-0-0-7320]). Our study showed that MAPK signaling subpathways participate in the pathological process of MI and are involved in lncRNAs. This could help to clarify the pathogenesis of MI.

In order to explore hub lncRNAs in the signal subpathways, the lncRNA-mRNA network was constructed through selecting the high degree of the subpathways. Then, a total of 13 hub lncRNAs were collected from the lncRNA-mRNA networks. Among these hub lncRNAs, MI associated transcript (MIAT), as an lncRNA, has been associated with a risk of MI ([@b10-etm-0-0-7320],[@b31-etm-0-0-7320]). It has been reported that MIAT expression levels are found to change in peripheral blood cells in patients who have suffered from MI, and smoking as a cardiovascular risk factor is found to be positively associated with MIAT ([@b32-etm-0-0-7320]). Apart from MIAT, other new hub lncRNAs for MI were found using subpathway-LINCE in this study. These hub lncRNAs could become potential diagnostic and therapeutic targets for MI.

In conclusion, using subpathway-LINCE to study MI lncRNA competitively regulated subpathways were gained, and the hub lncRNAs for MI in lncRNA-mRNA network were also obtained. Identifying the lncRNAs competitively regulated subpathways could help us to understand the pathogenesis of MI. The hub lncRNAs might represent novel regulators of MI and become new diagnostic and therapeutic targets for MI. Although the results in this study still need to be verified by experiments, these findings can help understand the roles of lncRNAs in MI.
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###### 

The diagram of the top 6 LncGenePairs.

  Lnc           Gene        corValue            P-value
  ------------- ----------- ------------------- --------------------------
  *TDRG1*       *HENMT1*    0.220560501443871   0.0299373311676897
  *LIMD1-AS1*   *LRRC56*    0.246484637523062   0.0149413386406672
  *LEF1-AS1*    *MAGEH1*    0.454787669314928   2.87221540632211×10^−6^
  *SNHG11*      *MRPL53*    0.680510717664986   1.75464015432401×10^−14^
  *LINC00485*   *NME7*      0.249365243302853   0.0137715015048636
  *LEF1-AS1*    *SLC27A5*   0.424727193889112   0.0000145102562949063

###### 

The diagram of the top 6 candidate different pathways.

  Index   Pathway_id                            Pathway_pvalue             p.adjust (FDR)
  ------- ------------------------------------- -------------------------- --------------------------
  05215   hsa05215: Prostate cancer             9.99732401124532×10^−12^   9.99732401124532×10^−12^
  05200   hsa05200: Pathways in cancer          8.45066918278111×10^−14^   8.45066918278111×10^−14^
  05220   hsa05220: Chronic myeloid leukemia    7.81664671803157×10^−17^   7.81664671803157×10^−17^
  04910   hsa04910: Insulin signaling pathway   0.0000771758111031205      0.0000771758111031205
  04510   hsa04510: Focal adhesion              6.65828057822821×10^−06^   6.65828057822821×10^−06^
  05166   hsa05166: HTLV--I infection           6.59501272205171×10^−07^   6.59501272205171×10^−07^

###### 

The diagram of the top 14 csLncRPs.

  path_name   matched_lnc   matched_gene
  ----------- ------------- --------------
  3008        *DLEU2*       *BMS1*
  3008        C14orf169     *BMS1*
  3008        *ERVK13-1*    *RCL1*
  3008        *PCBP1-AS1*   *POP1*
  3008        *ERVK13-1*    *MDN1*
  3008        *ERVK13-1*    *WDR75*
  3008        *ERVK13-1*    *UTP15*
  3008        *PDXDC2P*     *HEATR1*
  3008        *ERVK13-1*    *WDR43*
  3008        ERVK13--1     *LSG1*
  3010        *ERVK13-1*    *RPS6*
  3010        *ERVK13-1*    *RPS27*
  3010        *ERVK13-1*    RPS25
  3010        *ERVK13-1*    RPS3A

###### 

The diagram of the top six of the lncRNA competitively regulated subpathways.

  Pathway Id   Pathway name                  Molecule ratio (m2/x)   Bg ratio (m1/n)   Weight     P-value   FDR
  ------------ ----------------------------- ----------------------- ----------------- ---------- --------- --------------
  03010_1      Ribosome                      13/264                  13/26232          1.000000   \<0.001   0.0000E+0000
  03013_1      RNA transport                 11/264                  13/26232          1.241008   \<0.001   0.0000E+0000
  04010_1      MAPK signaling pathway        17/264                  25/26232          1.556393   \<0.001   0.0000E+0000
  04012_1      ErbB signaling pathway        10/264                  15/26232          1.736966   \<0.001   0.0000E+0000
  04062_1      Chemokine signaling pathway   14/264                  20/26232          1.514573   \<0.001   0.0000E+0000
  04066_1      HIF-1 signaling pathway       11/264                  16/26232          1.540568   \<0.001   0.0000E+0000

lncRNAs, long non-coding RNA; MAPK, mitogen activated protein kinase.
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